Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Pulmonx Corporation stock | $39.54

Learn how to easily invest in Pulmonx Corporation stock.

Pulmonx Corporation
- $0.11 ( - 0.28%)

Pulmonx Corporation is a medical devices business based in the US. Pulmonx Corporation shares (LUNG) are listed on the NASDAQ and all prices are listed in US Dollars. Pulmonx Corporation employs 220 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Pulmonx Corporation

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LUNG – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Pulmonx Corporation stock price (NASDAQ: LUNG)

Use our graph to track the performance of LUNG stocks over time.

Pulmonx Corporation shares at a glance

Information last updated 2021-10-16.
Latest market close$39.54
52-week range$35.81 - $69.48
50-day moving average $38.92
200-day moving average $41.25
Wall St. target price$55.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.39

Buy Pulmonx Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Pulmonx Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pulmonx Corporation price performance over time

Historical closes compared with the close of $39.54 from 2021-10-22

1 week (2021-10-15) -0.68%
1 month (2021-09-23) -0.18%
3 months (2021-07-23) -1.64%
6 months (2021-04-23) -12.07%
1 year (2020-10-23) -6.39%
2 years (2019-10-19) N/A
3 years (2018-10-19) N/A
5 years (2016-10-19) N/A

Pulmonx Corporation financials

Revenue TTM $41.9 million
Gross profit TTM $21.2 million
Return on assets TTM -15.38%
Return on equity TTM -35.49%
Profit margin -89.71%
Book value $5.74
Market capitalisation $1.5 billion

TTM: trailing 12 months

Shorting Pulmonx Corporation shares

There are currently 1.4 million Pulmonx Corporation shares held short by investors – that's known as Pulmonx Corporation's "short interest". This figure is 20.9% up from 1.2 million last month.

There are a few different ways that this level of interest in shorting Pulmonx Corporation shares can be evaluated.

Pulmonx Corporation's "short interest ratio" (SIR)

Pulmonx Corporation's "short interest ratio" (SIR) is the quantity of Pulmonx Corporation shares currently shorted divided by the average quantity of Pulmonx Corporation shares traded daily (recently around 369204.85933504). Pulmonx Corporation's SIR currently stands at 3.91. In other words for every 100,000 Pulmonx Corporation shares traded daily on the market, roughly 3910 shares are currently held short.

To gain some more context, you can compare Pulmonx Corporation's short interest ratio against those of similar companies.

However Pulmonx Corporation's short interest can also be evaluated against the total number of Pulmonx Corporation shares, or, against the total number of tradable Pulmonx Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pulmonx Corporation's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Pulmonx Corporation shares in existence, roughly 40 shares are currently held short) or 0.046% of the tradable shares (for every 100,000 tradable Pulmonx Corporation shares, roughly 46 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Pulmonx Corporation.

Find out more about how you can short Pulmonx Corporation stock.

Pulmonx Corporation share dividends

We're not expecting Pulmonx Corporation to pay a dividend over the next 12 months.

You may also wish to consider:

Pulmonx Corporation overview

Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California. .

Frequently asked questions

What percentage of Pulmonx Corporation is owned by insiders or institutions?
Currently 8.478% of Pulmonx Corporation shares are held by insiders and 78.207% by institutions.
How many people work for Pulmonx Corporation?
Latest data suggests 220 work at Pulmonx Corporation.
When does the fiscal year end for Pulmonx Corporation?
Pulmonx Corporation's fiscal year ends in December.
Where is Pulmonx Corporation based?
Pulmonx Corporation's address is: 700 Chesapeake Drive, Redwood City, CA, United States, 94063
What is Pulmonx Corporation's ISIN number?
Pulmonx Corporation's international securities identification number is: US7458481014

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site